Angiogenesis and Proliferation Index in Patients with Acute Leukemia: A Prospective Study
Table 1
Patient and control group characteristics.
Patients with AML ()
Patients with ALL ()
Control group ()
Age in years (median (range))
32 (14–65)
26 (13–66)
32 (13–60)
Sex (males/females)
15/11
18/11
9/10
*Immunophenotypic distribution of acute leukemia cases
4M0, 2M1, 10M2, 3APML, 1M4, 2M5, 2M6, 2M7
T-ALL = 13 B-ALL = 16
Not applicable
Hb g/dL (median (range))
6.5 (3.1–12.9)
6.5 (2.7–13.8)
11 (6.5–14)
TLC per cumm (median (range))
27,150 (900–2.48 lakh)
37,250 (1,200–5.02 lakh)
8000 (6,000–14,000)
Platelet per cumm (median (range))
34,000 (4000–5.21 lakhs)
27,500 (11,000–3.77 lakhs)
1.7 lakhs (1.3–3 lakhs)
Peripheral blood blast % (median (range))
71.5 (1–96)
82.5 (1–97)
NIL
Subleukemic cases % ()
17.86% (5)
16.67% (5)
NA
Bone marrow cellularity
Hypercellular = 25 Myelonecrosis = 1
Hypercellular = 29
Normal for age
Bone marrow aspirate blast % (median (range))
77 (23–96)
91 (52–98)
Nil
M0: AML with minimal differentiation, M1: AML without maturation, M2: AML with maturation, APML: acute promyelocytic leukemia, M4-Acute myelomonocytic leukemia, M5-Acute monoblastic and monocytic leukemia, M6: acute erythroid leukemia, M7: acute megakaryoblastic leukemia, B-ALL: B acute lymphoblastic leukemia, and T-ALL: T acute lymphoblastic leukemia.
